Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Account Payables (2021 - 2025)

Historic Change in Account Payables for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to $335924.0.

  • SAB Biotherapeutics' Change in Account Payables rose 14953.87% to $335924.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 66977.13%. This contributed to the annual value of $923323.0 for FY2024, which is 13417.54% up from last year.
  • Per SAB Biotherapeutics' latest filing, its Change in Account Payables stood at $335924.0 for Q3 2025, which was up 14953.87% from $138171.0 recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Change in Account Payables peaked at $2.0 million during Q2 2021, and registered a low of -$3.8 million during Q1 2021.
  • Moreover, its 5-year median value for Change in Account Payables was $134618.0 (2024), whereas its average is -$228161.9.
  • Its Change in Account Payables has fluctuated over the past 5 years, first crashed by 63355.95% in 2022, then surged by 65816.23% in 2024.
  • SAB Biotherapeutics' Change in Account Payables (Quarter) stood at $338327.0 in 2021, then crashed by 633.56% to -$1.8 million in 2022, then surged by 94.14% to -$105773.0 in 2023, then soared by 658.16% to $590385.0 in 2024, then plummeted by 43.1% to $335924.0 in 2025.
  • Its Change in Account Payables stands at $335924.0 for Q3 2025, versus $138171.0 for Q2 2025 and $684171.0 for Q1 2025.